| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e96496a9949403e2af2ca913e65bfec |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-555 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 |
| filingDate |
2005-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ded36a9179acdd50c10800be4ef31968
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb01922df3c8130876153b391040c950 |
| publicationDate |
2006-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006088475-A1 |
| titleOfInvention |
Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase |
| abstract |
The present invention relates to magnetic resonance imaging (MRI) contrast agent. In particular, the present invention provides MRI contrast agents that are sensitive to the enzyme beta-glucoronidase. The MRI contrast agents provide compositions and methods for non-invasive diagnostic imaging of tissues, including necrotic tumors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010029909-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8337813-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413621-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009269284-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8580231-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012207684-A1 |
| priorityDate |
2004-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |